Anlon Healthcare Limited has officially announced the allotment of bonus equity shares to its shareholders as per its latest regulatory filing. The Board of Directors, in a meeting held on April 27, 2026, approved the issuance of 26,57,57,500 fully paid-up bonus equity shares. These shares have a face value of Rs. 2 each and were distributed in a 1:1 ratio to eligible members. The record date for determining eligibility was fixed as April 24, 2026. Following this allotment, the company’s total paid-up equity share capital has increased to Rs. 1,06,30,30,000, consisting of 53,15,15,000 equity shares.

The detailed notice specifies that the meeting commenced at 09:00 A.M. and concluded shortly after at 9:15 A.M.. This action follows a series of earlier intimations provided by the company in March and April 2026 regarding its corporate actions, including a stock split and bonus issue. By doubling the number of outstanding shares through a 1:1 bonus, the company aims to reward its existing shareholders and potentially enhance liquidity in the market. The new shares carry the same rights as existing equity shares.

Anlon Healthcare Limited is a research-intensive pharmaceutical company based in Rajkot, Gujarat, specializing in the manufacture of high-purity Active Pharmaceutical Ingredients (APIs) and intermediates. In 2025, the company launched its IPO, listing on both the BSE and NSE on September 3, 2025. Throughout 2025, the company focused on expanding its product portfolio, which included 65 commercialized products and over 140 in various development stages. A significant recent update includes the company’s strategic shift toward becoming a complete pharmaceutical provider through the acquisition of a majority stake in Remember India Health Links Private Limited, enabling entry into finished dosage formulations.

For the last quarterly results of 2025 (Q3 FY26), the company reported a total income of Rs. 35.78 Crores, representing a massive 281.45% increase compared to the Rs. 9.38 Crores reported in the same period of 2024. Net profit for the December 2025 quarter stood at Rs. 5.15 Crores, a significant turnaround from the loss reported in the corresponding quarter of the previous year. The company maintains a strong promoter holding of 52.68% as of late 2025, with major individual promoters being Punitkumar Rameshbhai Rasadia and Meet Atulkumar Vachhani. Notable institutional interest includes the Neomile Growth Fund – Series I, which held a 4.54% stake in the company during this period.